AARTIDRUGS Aarti Drugs Q2 FY27 results (Jul–Sep 2026) and concall
Management summary
- Aarti Drugs delivered a record-setting performance in Q2 FY27.
- Firm API realisations amid geopolitical tensions in West Asia and accelerating formulations exports..
- Consolidated revenue crossed ₹829 crores, up 27% YoY.
- Operating leverage and backward integration at Saykha propelled EBITDA to a historic ₹138 crores at a 16.6% margin..
- While management conservatively guides for steady-state consolidated EBITDA margins of ~15%, robust export order visibility of four months in formulations and capacity expansions at Tarapur, Sarigam, and Baddi position the company for sustained multi
Source: Inve concall analysis and management guidance record.
Highlights
-
Record quarterly consolidated revenue of ₹829 crores, rising 27% YoY driven by 16% realization gains and 5% volume growth
-
Record quarterly EBITDA of ₹138 crores, up 63% YoY, with EBITDA margin at a 6-year high of 16.6% (up 370 bps YoY)
-
Profit after tax surged 83% YoY to ₹83 crores with PAT margin expanding 310 bps to 10.0%
-
Specialty chemicals segment revenue expanded 92% YoY to ₹72 crores supported by ~72% utilization at Saykha
What they filed
Q2 FY27: revenue up 26.5%, net profit up 84.4% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 557 | 677 | 591 | 653 | 602 +8% | 720 +6% | 703 +19% | 826 +26% |
| EBITDA | 62 | 93 | 74 | 84 | 55 −11% | 96 +3% | 98 +32% | 135 +61% |
| Net profit | 37 | 63 | 54 | 45 | 41 +11% | 55 −13% | 50 −7% | 83 +84% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Margin
Consolidated EBITDA Margin Margin · FY27 / Steady State · Medium confidence 15%
Volume
Standalone Segment Volume Growth Volume · H2 FY27 · Medium confidence 5% to 10%
Previously 10% odd → 5% to 10%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Sustainability of 16.6% EBITDA Margin and Formulations Margin Surge Direct
on the formulation side, this particular quarter, we made exceptional EBITDA margins of roughly around 28% due to good export orders... we do have export orders for almost 4 months more... But we are just being conservative that even if, you know, in a longer term steady state ba
Clarifies that while formulation EBITDA of 28% is bolstered by high-margin export orders with 4-month visibility, steady-state margin is around 20% and consolidated margin is conservatively expected around 15%.
Asked by Ankur Kumar, Alpha Capital
H2 FY27 Volume Growth Outlook and Customer Destocking Direct
Typically, the purchasing people at the formulation side, they try to refrain overstocking the product because the prices have suddenly gone up due to geopolitical reasons. So, there is a waiting game here... we will assume somewhere between 5% to 10% volume growth.
Management lowered its initial volume growth expectations from ~10% down to 5-10% because formulators are buying hand-to-mouth amidst elevated chemical/API prices.
Asked by Ankur Kumar, Alpha Capital
Unlock risks & concerns, Q3 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 5 risks, concerns & management red flags
- 4 watchlist triggers for Q3 FY27
- +6 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





